The Breast Cancer Index test, made by Biotheranostics, analyzes the activity of 11 genes to help predict the risk of early-stage, hormone-receptor-positive breast cancer coming back 5 to 10 years after diagnosis. The test can help women and their doctors decide if extending hormonal therapy 5 more years (for a total of 10 years of hormonal therapy) would be beneficial.
The Breast Cancer Index reports two results: how likely the cancer is to come back 5 to 10 years after diagnosis and if a woman is likely to benefit from taking hormonal therapy for a total of 10 years.
What are genomic tests?
Genomic tests analyze a sample of a cancer tumor to see how active certain genes are. The activity level of these genes affects the behavior of the cancer, including how likely it is to grow and spread. Genomic tests are used to help make decisions about whether more treatments after surgery would be beneficial.
While their names sound similar, genomic testing and genetic testing are very different.
Genetic testing is done on a sample of your blood, saliva, or other tissue and can tell if you have a change (also called a mutation) in a gene that is linked to a higher risk of breast cancer. See the Genetic Testing pages for more information.
Who’s eligible for the Breast Cancer Index test?
You may be eligible for the Breast Cancer Index test if:
- you were diagnosed with early-stage (stage I-III) breast cancer
- the cancer was hormone-receptor-positive
- there was no cancer in your lymph nodes (lymph node-negative disease) or the cancer is lymph-node positive and is in one, two, or three lymph nodes
- you’ve been taking hormonal therapy for 4 to 5 years and want to know if taking hormonal therapy for more time will be beneficial
Research has shown that extending hormonal therapy for 5 more years — for a total of 10 years of hormonal therapy — can offer benefits for some women diagnosed with early-stage, hormone-receptor-positive disease.
The Breast Cancer Index test is performed on preserved tissue that was removed during the original biopsy or surgery.
Because many women have troubling side effects, including hot flashes and joint pain, from hormonal therapy, they want to know if extending the time they take hormonal therapy is worth tolerating the side effects.
How does the Breast Cancer Index test work?
The Breast Cancer Index genomic test analyzes the activity of 11 genes that can influence how likely the cancer is to come back 5 to 10 years after diagnosis, as well as how likely a woman is to benefit from 5 additional years of hormonal therapy.
The Breast Cancer Index test returns two results:
- The BCI Prognostic result estimates how likely the cancer is to come back 5 to 10 years after diagnosis (late recurrence). The result is given as a percentage. So a prognostic result of 2.2% means that you have a 2.2% risk of the cancer coming back 5 to 10 years after diagnosis.
- The BCI Predictive result is reported as "yes" or "no." A yes result means you're likely to benefit from 5 more years of hormonal therapy. A no result means you're not likely to benefit from 5 more years of hormonal therapy.
Insurance coverage and financial assistance
The Medicare program and several other major insurance companies have agreed to cover the Breast Cancer Index test.
Biotheranostics, the company that makes the Breast Cancer Index test, has a Patient Services Team to help you with verifying insurance coverage and understanding any out-of-pocket costs. The company also has a patient assistance program that helps pay for testing. To contact the Patient Services Team, call 1-844-319-8111. The email address is firstname.lastname@example.org.
Other genomic tests
There are other genomics tests used to analyze breast cancer tumors. To learn more, click on the links below.
- The EndoPredict test is used to predict the risk of distant recurrence of early-stage, hormone-receptor-positive, HER2-negative breast cancer that is either node-negative or has up to three positive lymph nodes.
- The MammaPrint test is used to predict the risk of recurrence within 10 years after diagnosis of stage I or stage II breast cancer that is hormone-receptor-positive or hormone-receptor-negative.
- The Oncotype DX Breast Recurrence Score Test is used to predict the risk of distant recurrence of early-stage, hormone-receptor-positive, HER2-negative breast cancer, as well as how likely it is that a person diagnosed with this type of cancer will benefit from chemotherapy. The Oncotype DX Breast DCIS Score Test is used to predict the risk of recurrence of DCIS and/or the risk of a new invasive cancer developing in the same breast, as well as how likely it is that a woman diagnosed with DCIS will benefit from radiation after surgery.
- The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test) is used to predict the risk of distant recurrence for postmenopausal women within 10 years of diagnosis of early-stage, hormone-receptor-positive disease with up to three positive lymph nodes after 5 years of hormonal therapy.
Biotheranostics. Breast Cancer Index Website; 2021. Available at: https://breastcancerindex.com/
Can we help guide you?
Create a profile for better recommendations
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
What Is Breast Implant Illness?
Breast implant illness (BII) is a term that some women and doctors use to refer to a wide range...
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....